
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Gorlin Syndrome (Genetic Disorders) pipeline landscape.
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gorlin Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 1 respectively.
Gorlin Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Gorlin Syndrome (Genetic Disorders) pipeline landscape.
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gorlin Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 1 respectively.
Gorlin Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gorlin Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gorlin Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Genetic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Feldan Therapeutics Inc
Genentech USA Inc
Kintara Therapeutics Inc
Mayne Pharma Group Ltd
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
PellePharm Inc
Companies Mentioned
Feldan Therapeutics Inc
Genentech USA Inc
Kintara Therapeutics Inc
Mayne Pharma Group Ltd
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
PellePharm Inc
Table of Contents
77 Pages
- Introduction
- Global Markets Direct Report Coverage
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Overview
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Companies Involved in Therapeutics Development
- Feldan Therapeutics Inc
- Genentech USA Inc
- Kintara Therapeutics Inc
- Mayne Pharma Group Ltd
- Ono Pharmaceutical Co Ltd
- Palvella Therapeutics LLC
- PellePharm Inc
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drug Profiles
- FTX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- itraconazole - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nivolumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- patidegib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PTX-367 - Drug Profile
- Product Description
- Mechanism Of Action
- rostaporfin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sirolimus - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vismodegib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Product Development Milestones
- Featured News & Press Releases
- Oct 29, 2020: PellePharm to highlight clinical programs at the 29th congress of the European Academy of Dermatology and Venereology
- Jan 08, 2020: PellePharm initiates phase 2 clinical trial of Patidegib topical gel for people with high frequency basal cell carcinoma
- Dec 02, 2019: PellePharm completes enrollment of pivotal phase 3 clinical trial of Patidegib Topical Gel in patients with Gorlin Syndrome
- Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome
- Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS
- Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs
- Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference
- Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA
- Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
- May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting
- Feb 22, 2018: Adgero Biopharmaceuticals Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome
- Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency
- Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome
- Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
- Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Feldan Therapeutics Inc, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Genentech USA Inc, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Kintara Therapeutics Inc, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Mayne Pharma Group Ltd, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Palvella Therapeutics LLC, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by PellePharm Inc, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects, 2022
- Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.